



Market Announcement

20 January 2022

Telix Pharmaceuticals Limited (ASX: TLX) – Trading Halt

Description

The securities of Telix Pharmaceuticals Limited ('TLX') will be placed in trading halt at the request of TLX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 24 January 2022 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)



Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne, Victoria, 3051 Australia
www.telixpharma.com

20 January 2022

Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)
Level 4, North Tower
Rialto Towers
525 Collins Street
Melbourne VIC 3000

By email: tradinghaltsmelbourne@asx.com.au

Dear Melissa

REQUEST FOR TRADING HALT

Telix Pharmaceuticals Limited (ASX: TLX) (Company) requests an immediate trading halt be granted for all of its securities.

In accordance with Listing Rule 17.1, the Company advises:

- the trading halt is requested pending an announcement regarding a material capital raise;
- the trading halt is requested to apply until the earlier of an announcement by the Company on the completion of the capital raise, or the commencement of normal trading on Monday, 24 January 2022; and
- the Company is not aware of any reason why a trading halt should not be granted.

Authorised for release by the Board of Telix Pharmaceuticals Limited.

A handwritten signature in blue ink, appearing to read "Melanie Farris".

Melanie Farris
Group Company Secretary